MARATTO

article · International Journal of Rheumatic Diseases

Serum Endocan in Systemic Lupus Erythematosus: Implication for Endothelial Dysfunction and Cardiovascular Risk

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Elevated serum levels of endocan in SLE patients may be associated with subclinical atherosclerosis and endothelial dysfunction.

Research topics

  • Inflammation biomarkers and pathways
  • Galectins and Cancer Biology
  • Apelin-related biomedical research

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1111/1756-185x.70590

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.